Anecdotal reports of transient disturbances in NMJ transmission have led to the occasional use of AChE enzyme inhibitors in ALS patients despite the lack of evidence of an effect in a controlled trial [17]. The gene discussed is ACHE; the disease is amyotrophic lateral sclerosis.